Understanding the Importance of Capsules in Dry Powder Inhalers.
capsule
dry powder inhaler
inhalation
pulmonary drug delivery
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
16 Nov 2021
16 Nov 2021
Historique:
received:
27
09
2021
revised:
27
10
2021
accepted:
06
11
2021
entrez:
27
11
2021
pubmed:
28
11
2021
medline:
28
11
2021
Statut:
epublish
Résumé
Pulmonary drug delivery is currently the focus of research and development because of its potential to produce maximum therapeutic benefit to patients by directing the drug straight to the lung disease site. Among all the available delivery options, one popular, proven and convenient inhaler device is the capsule-based dry powder inhaler (cDPI) for the treatment of an increasingly diverse range of diseases. cDPIs use a hard capsule that contains a powder formulation which consists of a mixture of a micronized drug and a carrier usually the lactose, known for its good lung tolerance. The capsule is either inserted into the device during manufacturer or by the patient prior to use. After perforating, opening or cut the capsule in the device, patients take a deep and rapid breath to inhale the powder, using air as the vector of drug displacement. The system is simple, relatively cheap and characterized by a lower carbon footprint than that of pressurized metered dose inhalers. This article reviews cDPI technology, focusing particularly on the importance of capsule characteristics and their function as a drug reservoir in cDPIs.
Identifiants
pubmed: 34834351
pii: pharmaceutics13111936
doi: 10.3390/pharmaceutics13111936
pmc: PMC8623721
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Int J Pharm. 2016 Apr 30;503(1-2):36-40
pubmed: 26899981
Thorax. 2020 Jan;75(1):82-84
pubmed: 31699805
AAPS PharmSciTech. 2015 Jun;16(3):479-90
pubmed: 25964142
J Aerosol Med. 2007 Spring;20(1):38-44
pubmed: 17388751
Int J Pharm. 2015 Jan 30;478(2):796-803
pubmed: 25526672
Int J Pharm. 2016 Mar 16;500(1-2):316-25
pubmed: 26806464
Chronic Obstr Pulm Dis. 2020 Apr;7(2):118-129
pubmed: 32324983
Eur J Pharm Sci. 2018 Feb 15;113:64-76
pubmed: 29104067
J Pharm Pharm Sci. 2010;13(3):428-42
pubmed: 21092714
Med Eng Phys. 2012 May;34(4):409-27
pubmed: 22277307
Curr Med Res Opin. 2010 Nov;26(11):2527-33
pubmed: 20843166
AAPS J. 2013 Apr;15(2):511-22
pubmed: 23371759
Drug Dev Ind Pharm. 2008 Aug;34(8):870-6
pubmed: 18686093
AAPS PharmSciTech. 2014 Apr;15(2):434-55
pubmed: 24452499
Int J Pharm. 2015 Jun 20;487(1-2):197-204
pubmed: 25843756
J Drug Assess. 2013 Feb 01;2(1):11-6
pubmed: 27536432
Expert Opin Drug Deliv. 2020 Jul;17(7):1025-1039
pubmed: 32551990
Int J Pharm. 2015 Aug 15;492(1-2):258-63
pubmed: 26196275
AAPS PharmSciTech. 2018 Jan;19(1):251-261
pubmed: 28695328
Int J Pharm. 2018 Sep 5;548(1):182-191
pubmed: 29883795
J Control Release. 2020 Jul 10;323:412-420
pubmed: 32325175
Multidiscip Respir Med. 2017 May 22;12:11
pubmed: 28536654
Pharmaceutics. 2021 May 11;13(5):
pubmed: 34064698
Handb Exp Pharmacol. 2019;260:143-159
pubmed: 31792683
NPJ Prim Care Respir Med. 2016 Nov 24;26:16079
pubmed: 27883002
Expert Opin Drug Deliv. 2017 Apr;14(4):499-512
pubmed: 27534768
Prim Care Respir J. 2012 Jun;21(2):208-13
pubmed: 22336894
Int J Pharm. 2018 Dec 20;553(1-2):47-56
pubmed: 30321640
Pharmaceutics. 2021 Aug 06;13(8):
pubmed: 34452174
Eur Respir J. 2008 Jan;31(1):78-83
pubmed: 17898020
Drug Dev Ind Pharm. 2002 Jul;28(6):641-54
pubmed: 12149956
AAPS PharmSciTech. 2020 May 12;21(4):128
pubmed: 32399597
Int J Pharm. 2013 Nov 18;456(2):545-52
pubmed: 23965433
Eur Respir J. 2011 Jun;37(6):1308-31
pubmed: 21310878